Produces local estrogen effect on the mucosa at the bottom of the female reproductive tract, thereby restoring its nutritional function

This product is a semi-synthetic progesterone derivative, which has a certain inhibitory effect on hormone-dependent tumors. Its mechanism of action is the same as that of medroxyprogesterone, which may be through the influence of pituitary gonadotropin secretion, controlling the development and growth of ovarian follicles, thereby reducing the production of estrogen. It acts on estrogen receptors, preventing their synthesis and reuse, interfering with their binding with estrogen, and inhibiting tumor cell growth. In addition, it can also antagonize glucocorticoid receptors and interfere with the interaction between steroid hormone receptors and regulatory proteins related to cell growth and differentiation.

Extract from the above information

Nisoldipine is a dihydropyridine calcium channel antagonist that inhibits the influx of calcium ions through the cell membrane into vascular smooth muscle and myocardial cells. It can reversibly compete with other dihydropyridine drugs for binding to calcium ion channels. Since the contraction process of vascular smooth muscle depends on the entry of extracellular calcium into myocytes through specific ion channels, the inhibition of calcium channels will lead to the dilation of arterioles. In vitro tests have shown that the effect of nisoldipine on the contraction process is selective, and its effect on vascular smooth muscle is stronger than that on myocardium. Although nisoldipine, like other dihydropyridine calcium channel blockers, has a negative inotropic effect in vitro, studies conducted in anesthetized animals have shown that the dose of nisoldipine that produces vasodilation is lower than the dose that affects myocardial contractility.